Clinical TrialMay 4, 2026, 08:07 AM
Candel Therapeutics to Host Call on Phase 3 Prostate Cancer Data
AI Summary
Candel Therapeutics, Inc. announced it will host a webcast and conference call on May 15, 2026, to discuss extended follow-up data from its pivotal Phase 3 clinical trial of aglatimagene besadenovec (CAN-2409). The trial focuses on patients with intermediate- to high-risk localized prostate cancer. The discussion will follow an oral plenary presentation of these data at the American Urological Association (AUA) 2026 Annual Meeting and will feature insights from prominent prostate cancer specialists.
Key Highlights
- Candel Therapeutics to host a webcast and conference call on Friday, May 15, 2026, at 1:00 PM ET.
- The call will discuss extended follow-up data from the phase 3 clinical trial of aglatimagene besadenovec (CAN-2409).
- The trial involves patients with intermediate- to high-risk localized prostate cancer.
- Data will be presented at the American Urological Association (AUA) 2026 Annual Meeting.
- Leading prostate cancer specialists, including Neal D. Shore, M.D., Jonathan D. Tward, M.D., Ph.D., and Daniel J. George, M.D., will provide insights.
Price Impact
More from CADL